Commercial Evidence: Turning field intelligence into actionable insights
Dr Müller prescribes a therapy for six months, then suddenly stops. The CRM system shows that the field rep called on schedule, delivered the primary brand message, and logged a positive interaction. What the call report fails to capture is that the regional sickness fund revised its reimbursement criteria three weeks ago. This is a treatment barrier that every rep in the territory knows, yet, headquarters remains unaware of the shift. By the time trailing sales data surfaces the drop-off weeks later, patients have already transitioned to alternative therapies.
Critical observations gathered during healthcare professional (HCP) interactions rarely inform commercial strategy in time to make a difference. Traditional drop-down reporting systems capture what occurred — a meeting held, a brochure delivered, a sample dropped off — but tracking activity alone misses the context around why clinical behaviour shifted.
Closing this gap requires a structural shift in how interaction data is collected and processed across channels. In the field, an agentic CRM system that compliantly captures field interaction details with agentic voice and free text capabilities, enables reps to record qualitative insights. Embedded AI automatically reviews entries for compliance, extracts strategic details, and populates structured records to eliminate manual administrative burdens.
These Agentic Call Reports help turn field observations into scalable, actionable insights generating Commercial Evidence — real-world context revealing the exact intent signals, content gaps, and therapeutic barriers facing physicians and patients. Seeing the full picture, commercial teams sharpen customer targeting, prioritise field activities, and personalise messaging to address what is top-of-mind for each clinician, replacing generic outreach with relevant interactions.
From field activity records to actionable insights
Daily HCP-rep conversations contain the answers to biopharma’s most persistent questions: What do providers truly believe about a therapy? Where do they stand on the adoption journey? Which patient archetypes trigger clinical interest or resistance?
Dr Müller did not stop prescribing due to a loss of confidence in the product's science; an unmapped administrative shift created the roadblock. While traditional call reports miss this critical context, 65% of Agentic Call Reports identify treatment barriers, such as reimbursement uncertainty, to help prioritise strategic actions.
Instead of tracking only calls completed or emails sent, Commercial Evidence helps measure barrier resolution, message effectiveness, and adoption progression. To turn individual anecdotes into actionable metrics, the system prompts field reps with specific follow-up questions during capture: What specifically drove the physician’s hesitation? Did the HCP indicate reimbursement concerns? Was the objection clinical, operational, or economic?
With the Agentic Call Report, biopharmas gather real-world insights that standard surveys, claims datasets, or pick lists overlook. Rather than relying solely on periodic market research or focus panels, commercial teams validate strategies against actual data inputted directly by the field. With the Agentic Call Report, organisations capture insights compliantly and create personalised strategies to improve treatment adoption.
From insights to guidance for prioritised field actions
When commercial teams transform qualitative observations into actionable insights, CRM evolves from a system of record to a system of guidance by elevating routine visits into consultative discussions. This shift is critical as direct access to HCPs continues to narrow, with 50% limiting engagement to three or fewer companies. Securing a place within this selective group depends on the biopharma's ability to deliver immediate, tailored value.
Commercial Evidence redefines field engagement by providing the detailed context necessary to make every meeting count. When a rep enters a clinic equipped with precise pre-call intelligence — knowing exactly which messages resonate, what objections surfaced during a previous visit, who the key account influencers are, and what administrative friction delays approvals — the relationship shifts from a promotional sales pitch to a consultative partnership.
Fewer, higher-quality interactions guided by tailored insight consistently outperform reach-and-frequency approaches. For example, resolving the specific regional reimbursement issue that caused Dr Müller to halt prescriptions yields far greater value than executing a high volume of calls to accounts known to be politely dismissive. Reps who demonstrate continuity of context, problem-solving intent, and genuine responsiveness retain and deepen customer access over time.
Biopharmas use Commercial Evidence to prioritise field actions through qualitative field insights to map account dynamics. When a field rep notes referral patterns between local treatment centres, commercial leaders gain visibility into who influences adoption decisions within a regional ecosystem. Sales teams can then engage those prescribers as peer influencers to help other providers progress along the adoption journey with greater confidence.
From field guidance to closed-loop marketing
The true value of Commercial Evidence emerges when ground-level insights feed back into commercial operating models. A common breakdown in life sciences marketing occurs when central brand strategy operates isolated from clinic realities. Commercial Evidence resolves this by establishing a two-way feedback loop between the field and home-office strategy.
Biopharmas demonstrate this integration by using Agentic Call Report capabilities in their CRM to streamline how intelligence moves from the clinic to central leadership. Instead of spending time manually entering data through pick lists after each HCP interaction, reps compliantly capture narrative insights surfacing market dynamics as they happen. Embedded AI capabilities not only simplify data capture, but quickly synthesise qualitative trends to democratise expertise across the organisation.
With Commercial Evidence accessible across functional units, marketing teams can calibrate messaging with high precision based on evolving market perceptions, evidence gaps, and unmet clinical needs. When narrative field entries reveal a pattern of reimbursement friction — such as the regional policy shift that impacted Dr Müller — brand teams can rapidly deliver updated coverage guides and support materials. By continuously tailoring resources to resolve these specific friction points, commercial teams equip field forces with high-value pre-call intelligence, completing a closed-loop operating model where enterprise strategy continuously adapts to clinic floor reality.
Measuring the return on AI
Commercial Evidence elevates CRM to an active intelligence engine. Automating qualitative data extraction and compliance checks eliminates routine administrative burdens, allowing field forces to focus on meaningful engagement.
As the sales force evolves from promotional distribution channels into strategic sources of customer intelligence, performance frameworks across the industry are adapting accordingly. Evaluating field success solely on prescription volume risks prioritising call quantity over relationship quality. Modern evaluation models increasingly measure strategic contribution: barrier resolution, qualitative insight capture, and account progression.
By moving from basic activity records to actionable insights, field guidance, and closed-loop marketing, biopharmas unlock measurable returns on AI investment (ROAI) across three core operational pillars:
- Sharper customer targeting: Moves commercial strategy beyond static, annual segmentation models. Teams monitor shifting sentiment in real time, tracking how prescribers move along the adoption journey and pinpointing precisely where clinical hesitancy occurs.
- Prioritised field execution: Replaces generic call plans with actionable pre-call intelligence. Field personnel receive timely, contextual insights that empower them to engage the right physicians with relevant solutions at the exact moment of need.
- Personalised brand marketing: Bridges the gap between central marketing teams and the clinic floor. Brand leaders can continually refine campaign collateral and promotional assets to directly address the actual objections, access friction, and clinical questions raised during visits.
Ultimately, replacing broad promotional outreach with precision engagement ensures clinicians like Dr Müller receive the exact support needed to navigate treatment barriers, accelerating patient access to life-changing therapies.
About the author
Aaron Bean is VP, Commercial Business Consulting Leader, Europe & Asia, at Veeva Systems. He leads Veeva’s European consulting practice based in London. Bean has 18+ years of experience working with life sciences companies across Europe, focused on commercial strategy through to execution. He specialises in commercial innovation, effectiveness, and digital transformation to help companies deliver great customer experiences and tangible, sustainable business impact. He is passionate about the infusion of technology and data to drive scalable and sustainable business transformation. Prior to joining Veeva, Bean led EY’s Life Sciences consulting practice in the UK&I, and before that was at Accenture in its marketing sciences division. He has a First Class BSc with Honours in Business and Management from Aston University.
About Veeva Systems
Veeva delivers the industry cloud for life sciences with applications, agents, data, and consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com/eu.
